Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — H1 2025 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, Aug 20, 2025
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2025.08.20
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Results Report H1/2025 Agenda
Operational Results Report H1/2025 Operational Highlights H1/2025 Financial Performance 01 H1/2025 Operational Highlights 2025 Outlook 2
Slide 4: Strong Revenue Growth in H1/2025 with Overseas Markets Expansion
3,000 2,649 2,971 3 Strong Revenue Growth in H1/2025 Consolidated Revenue 2,000 2.18 2.72 營運成果報告 with Overseas Markets Expansion Consolidated Operating Profit 1,000 800 818 2 EPS Revenue Overview - H1/2024 H1/2025 1 H1/2025 Operational √ Consolidated Revenue √ Consolidated Operating Profit √ EPS Hig
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results 營運成果報告 H1/2025 Operational Highlights H1/2025 Financial Performance 2025 Outlook 4
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation 營運成果報告 • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets H1/2025 Operational Highlights Oncology 2025 2
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. H1/2025 • Deepen cooperation with
Slide 8: 02 H1/2025 Financial Performance
Operational Results Report H1/2025 Operational Highlights H1/2025 Financial Performance 02 H1/2025 Financial Performance 2025 Outlook 7
Slide 9: H1/2025 Financial Performance
H1/2025 Financial Performance Operational Results Report Income Statement （Unit: NT Thousand, H1/2025 H1/2024 YoY % H1/2025 Financial Performance except EPS） H1/2025 Net Sales 2,970,900 2,648,256 12% • YoY consolidated revenue was 29.7 billion, +12% due to Operational the high growth of overseas mar
Slide 10: H1/2025 Steady Revenue Growth
H1/2025 Steady Revenue Growth Operational Results Report H1/2025 Revenue Breakdown H1/2025 Revenue Growth H1/2025 Operational Highlights Product Category % Revenue (NT Mn) 3,000 18% 68 13 1 -30 2,950 2,971 Oncology 40% H1/2025 3% 2,900 115 Financial 2,850 Performance Intensive Care 2,800 156 2,750 H
Slide 11: 03 2025 Outlook
Operational Results Report H1/2025 Operational Highlights H1/2025 Financial Performance 03 2025 Outlook 2025 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report Strengthen Global Deployment H1/2025 Operational Highlights 1 Explore potential products and expand international market through authorization, distribution, strategic cooperation and M&A. International Regulations License